Background. Lymphoma incidence is increased among human immunodeficiency virus (HIV)-infected individuals soon after antiretroviral therapy (ART), perhaps due to unmasking immune reconstitution inflammatory syndrome (IRIS). Clinical characteristics and survival for unmasking lymphoma IRIS have not been described.
Individuals infected with human immunodeficiency virus (HIV) have increased incidence of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) during the first 6 months after antiretroviral therapy (ART) [1] [2] [3] . This may be due to immune reconstitution inflammatory syndrome (IRIS). IRIS is well described for opportunistic infections and Kaposi sarcoma (KS), and is classified as "unmasking" when it leads to a new HIV-associated condition that was not evident prior to ART, or "paradoxical" when it leads to worsening of a condition recognized and treated prior to ART [4] [5] [6] [7] [8] [9] [10] [11] . Clinical characteristics and survival for lymphoma IRIS are unknown. We identified patients in a large HIV-associated lymphoma cohort meeting a uniformly applied unmasking IRIS case definition, and compared lymphoma IRIS and non-IRIS cases. Our data did not allow us to distinguish paradoxical lymphoma IRIS from refractory lymphoma due to aggressive tumor behavior alone, and we therefore focused on unmasking lymphoma IRIS.
METHODS

Patients
The Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) cohort includes >27 000 HIVinfected adults 18 years and older receiving care since 1 January 1995 at 8 United States CFAR sites [12] . We examined individuals with NHL or HL diagnosed between 1 January 1996 and 31 December 2011. Follow-up was administratively censored on 31 December 2011.
Procedures
CNICS captures comprehensive clinical data through electronic health records (EHRs) and other institutional data systems at each site. Historical information are collected upon cohort entry. Data quality is assessed prior to transmission to CNICS. After integration into the CNICS repository, data undergo extensive quality assurance. A standardized cancer verification procedure has been established [13] , and cancer diagnoses are reviewed to collect information regarding type, histology, stage, and treatment. If >1 lymphoma diagnosis or relapse was recorded, we analyzed the first occurrence. Patients are enrolled in CNICS upon entering care at HIV clinics, but data may be available from EHRs prior to enrollment. To increase generalizability, we included individuals diagnosed with lymphoma before and after CNICS entry to avoid excluding patients newly diagnosed with HIV, out of care, or transferring HIV care at the time of lymphoma diagnosis. Mortality data are obtained from clinic sources and the Social Security Death Index.
Unmasking lymphoma IRIS was defined as NHL or HL diagnosed within 6 months after ART initiation with virologic suppression, defined as ≥0.5 log reduction in HIV RNA log 10 copies/mL. This was modified from existing KS IRIS definitions, and IRIS definitions for tuberculous and cryptococcal disease taken from the International Network for the Study of HIVassociated IRIS [4, 5, 10, 11, 14] . For HIV RNA, the pre-ART measurement was the closest value to ART start date within 3 months before the ART start date. Post-ART HIV RNA at lymphoma diagnosis was the value closest to lymphoma diagnosis, which occurred after ART start date and up to 3 months after lymphoma diagnosis. For non-IRIS cases, HIV RNA at lymphoma diagnosis was the value closest to lymphoma diagnosis beginning 3 months before until 3 months after. Suppressed HIV RNA was defined as <400 copies/mL. CD4 count at lymphoma diagnosis was the value closest to lymphoma diagnosis beginning 3 months before until 3 months after. Nadir CD4 count was the lowest CD4 count at any time on or before the date of CD4 count at lymphoma diagnosis. Hepatitis B coinfection was defined as any positive hepatitis B surface antigen or DNA result, and hepatitis C coinfection as any positive hepatitis C antibody or RNA result, before or until 6 months after lymphoma diagnosis.
Statistical Analysis
Differences between IRIS and non-IRIS were assessed using χ 2 or Fisher exact test, 1-way analysis of variance, and KruskalWallis test. To assess CD4 and HIV RNA during the 12 months before and after lymphoma diagnosis, summative curves were derived by plotting median and interquartile values at each monthly time point across all patients within each group. Individual patient-level CD4 and HIV RNA curves were generated by plotting all available measurements for each patient over this time period and imputing values in between assuming a linear trajectory. To estimate trends over the entire 2-year period, first available measurements within the time period were carried backward to 12 months before lymphoma diagnosis, and last available measurements were carried forward to 12 months after lymphoma diagnosis. CD4 and HIV RNA values for each patient at each monthly time point were assigned based on the value at which individual curves intersected each monthly time point.
Mortality rates were calculated as number of deaths per 100 person-years of follow-up. Follow-up time was calculated from date of lymphoma diagnosis until administrative censoring, death, or loss to follow-up. Loss to follow-up date was based on last date of any clinical activity in CNICS. To minimize survival bias, patients with lymphoma diagnosed before HIV clinic attendance and CNICS enrollment were treated as late entries who contributed follow-up time only after CNICS entry [15] . Kaplan-Meier curves were used to estimate overall survival after lymphoma diagnosis, and Cox proportional hazards were used to assess differences in survival between IRIS and non-IRIS.
We conducted sensitivity analyses varying the IRIS definition to include (1) lymphoma within 3 months of ART accompanied by ≥0.5 log HIV RNA reduction; (2) lymphoma within 6 months of ART accompanied by ≥1 log HIV RNA reduction; and (3) lymphoma within 3 months of ART accompanied by ≥1 log HIV RNA reduction. We performed sensitivity analyses restricted to patients diagnosed with lymphoma after CNICS enrollment. All analyses were conducted using SAS version 9.3. A 2-sided α value of .05 was used to assess statistical significance. Patients were excluded from analyses that included variables for which data were missing. Patients with lymphoma diagnosed before CNICS enrollment were more likely to have any missing value for CD4 count at lymphoma diagnosis, nadir CD4 count, or HIV RNA at lymphoma diagnosis compared with patients for whom lymphoma was diagnosed after cohort entry (44% vs 12%, P < .0001). CD4 count and HIV RNA measurements at lymphoma diagnosis differed from lymphoma diagnosis date by a median of 12 days (IQR, 4-27) and 13 days (IQR, 4-29), respectively.
RESULTS
Of
Fifty-six of 482 patients (12%) met the unmasking lymphoma IRIS case definition. Among non-IRIS cases, 9 patients were diagnosed with lymphoma within 6 months after ART, but without documented HIV RNA reduction as required by the unmasking IRIS case definition. Baseline characteristics for IRIS and non-IRIS cases are shown in Table 1 . Among IRIS cases, 12 (21%) had HL, 22 (39%) diffuse large B-cell lymphoma (DLBCL), 5 (9%) Burkitt lymphoma (BL), 10 (18%) primary central nervous system lymphoma (PCNSL), and 7 (13%) other NHL. Median CD4 count at lymphoma diagnosis among IRIS cases was 173 cells/mL (IQR, 73-302), and 48% had HIV RNA <400 copies/ mL. No significant differences were identified between IRIS and non-IRIS, excepting more frequent hepatitis B and C (30% vs 19%, P = .05), more frequent prior AIDS (91% vs 79%, P = .03), lower HIV RNA (2.7 vs 4.5 log 10 copies/mL, P < .0001), and higher proportion with suppressed HIV RNA (48% vs 30%, P = .0009) among IRIS cases. HIV RNA differences resulted in part from the IRIS case definition, which required virologic response to ART. No significant differences in lymphoma subtype distribution were identified between IRIS and non-IRIS cases, although numerically higher proportions of HL (21% vs 16%, P = .30) and PCNSL (18% vs 10%, P = .09) were observed among IRIS. Unmasking lymphoma IRIS cases were on ART for a median 2.2 months (IQR, 0.9-3.5) before lymphoma diagnosis. Among 426 non-IRIS cases, 175 (41%) were on ART at lymphoma diagnosis for a median 20.3 months (IQR, 7.5-42.9), of whom 83 of 142 (58%) with an HIV RNA value recorded at lymphoma diagnosis had suppressed HIV RNA. Differences in ART duration between IRIS and non-IRIS cases were influenced by the IRIS case definition, which required lymphoma diagnosis within 6 months after ART initiation.
Median CD4 count and HIV RNA with interquartile ranges during the 12 months before and after lymphoma diagnosis are shown in Figure 1 for IRIS, non-IRIS on ART, and non-IRIS off ART at lymphoma diagnosis. During the 24-month window, (Figure 2 ). When follow-up time was partitioned at 6-month and 1-year time points, a pattern of increased early mortality followed by reduced late mortality was suggested for IRIS ( . This pattern of similar long-term survival but possibly increased early mortality was also observed when IRIS were separately compared with non-IRIS cases on ART at lymphoma diagnosis, and also to non-IRIS cases off ART. Despite limitations from small numbers of IRIS cases within histologic groups, possibly increased early mortality for IRIS was most strongly suggested for NHL, particularly BL and PCNSL. Sensitivity analyses varying the IRIS case definition were conducted as follows: (1) lymphoma within 3 months of ART with ≥0.5 log HIV RNA reduction (n = 33); (2) lymphoma within 6 months of ART with ≥1 log HIV RNA reduction (n = 41); and (3) lymphoma within 3 months of ART with ≥1 log HIV RNA reduction (n = 23). In these analyses, IRIS and non-IRIS were similar overall, with consistent demonstration of more frequent hepatitis B and C and lower HIV RNA at lymphoma diagnosis among IRIS cases, and consistently higher PCNSL proportions reaching statistical significance using IRIS case definitions (1) and (2) . Similar overall survival between IRIS and non-IRIS cases 5 years after lymphoma diagnosis was also observed across varying IRIS case definitions, with possibly increased early mortality for IRIS consistently demonstrated. When analyses were restricted to 281 patients with lymphoma diagnosed after CNICS enrollment, 56 (20%) were classified as IRIS and 225 as non-IRIS, with findings otherwise similar.
DISCUSSION
In a multicenter HIV-associated lymphoma cohort, 12% of patients met a uniformly applied unmasking IRIS case definition. These results are descriptive, but important given that lymphoma IRIS has not been characterized in detail. Our findings support the concept of lymphoma IRIS as a distinct and definable entity, and extend previous cohort studies demonstrating increased lymphoma incidence during the first 6 months after ART [1] [2] [3] .
Lymphomagenesis in HIV-infected individuals is complex, involving viral oncogens such as Epstein-Barr virus (EBV), immune surveillance in the germinal center, tumor microenvironment interactions, activation of cell signaling pathways such as nuclear factor-κB, and chronic B-cell activation, all of which vary in relative contribution across histologic subtypes [16] [17] [18] [19] [20] [21] [22] [23] . Although no significant differences were observed in histologic distribution between lymphoma IRIS and non-IRIS, there was a suggestion of increased HL and PCNSL among IRIS cases. This should be interpreted with caution given small numbers of IRIS cases. However, HL and PCNSL are the HIV-associated lymphoma subtypes for which EBV is most consistently demonstrated in tumor specimens [16] . Examining EBV status among lymphoma IRIS patients may be informative, particularly since other herpesviruses, including KS-associated herpesvirus, cytomegalovirus, herpes simplex virus, and varicella zoster virus, are commonly implicated in IRIS presentations [6] [7] [8] . Possibly increased hepatitis B/C coinfection among IRIS cases may also be notable. Unlike EBV, which directly infects and transforms lymphocytes, hepatitis B and C increase NHL risk by inducing chronic immune activation and B-cell stimulation [24] . HIVassociated lymphomas, in which immune activation plays a pathogenically stronger role, may be more susceptible to IRIS effects.
Our results are consistent with the IRIS literature. First, 12% of HIV-associated lymphoma patients met an unmasking lymphoma IRIS case definition. IRIS is common after ART, occurring in 5%-15% of ART initiators with increased risk among those with advanced immunosuppression [6-8, 11, 14] . HIVinfected lymphoma patients present with advanced immunosuppression even in the ART era [25] . Identifying unmasking IRIS in a significant number of patients from a large HIVassociated lymphoma cohort may therefore not be surprising. Unmasking lymphoma IRIS cases were on ART for a median 2.2 months prior to lymphoma diagnosis, consistent with peak IRIS incidence within the first 3 months on ART [6, 7] . We also observed possibly increased early mortality among lymphoma IRIS cases, but similar long-term outcomes to non-IRIS, as with previous IRIS descriptions [6, 7] . This pattern was particularly observed for NHL. Notably, PCNSL IRIS cases had much worse outcomes than non-IRIS cases. Increased mortality has been described for other forms of IRIS involving the CNS, as excess intracranial inflammation leads to significant morbidity and mortality [6, 8, [26] [27] [28] . BL IRIS also appeared to have worse survival than non-IRIS, perhaps reflecting IRIS in a highly proliferative lymphoma subtype with frequent extranodal and CNS involvement [16, 29, 30] . Detailed lymphoma IRIS studies may elucidate immunologic mechanisms of lymphoma control. Treating human cancer by stimulating tumor-specific T lymphocytes is a promising therapeutic strategy. Immune activating cancer therapies include inhibitors of programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) signaling [31, 32] . Activation of the PD-1 pathway is found in aggressive B-cell lymphomas, as well as virus-and immunodeficiencyassociated malignancies [33] . Some immune-based cancer treatments are characterized by immunologic toxicities that may require systemic corticosteroids and immunomodulatory therapies not unlike severe IRIS, but a substantial rate of durable cancer remissions [34] [35] [36] . HIV-associated IRIS is characterized by a rapid increase in CD4 cells, lymphocyte proliferation responses, immune activation, and pathogen-specific delayed hypersensitivity [37] [38] [39] [40] . Despite small numbers, we observed possibly increased early mortality followed by reduced late mortality among IRIS cases, with near plateauing of survival after 1 year. The similarity of this observation to findings from clinical trials of immune-based cancer treatments suggest that more detailed studies of lymphoma IRIS might yield immunobiologic insights with relevance even for HIV-uninfected patients.
Our research has several limitations. First, existing IRIS case definitions are not standardized. We applied a uniform case definition drawn from the literature, and varied this in sensitivity analyses yielding consistent results. Second, subclinical lymphoma leading to care-seeking behavior and ART initiation before lymphoma diagnosis could not be excluded. Third, data did not allow for a distinction between refractory lymphoma and paradoxical lymphoma IRIS, in which ART after lymphoma diagnosis may have led to clinical worsening. Paradoxical lymphoma IRIS would have been classified as non-IRIS, perhaps mitigating differences between groups. Fourth, data are observational and unadjusted, and associations may be due to measured and unmeasured confounding. Given small numbers of IRIS cases within histologic groups, we did not adjust for other covariates, although measured covariates were similar overall between IRIS and non-IRIS. Fifth, CNICS enrollment requires HIV clinic attendance, and patients with lymphoma diagnosis preceding CNICS enrollment are included, for whom data may have been incomplete. We sought to maintain generalizability to patients not receiving HIV care or newly diagnosed with HIV at lymphoma diagnosis. We minimized bias by analyzing followup time only after CNICS entry and sought to ensure that "immortal" person-time between lymphoma diagnosis and cohort entry was not inappropriately counted. We restricted analyses to patients with lymphoma diagnosis after CNICS enrollment and found consistent results. However, survival for patients with lymphoma before CNICS enrollment may not be accurately reflected. Sixth, detailed information regarding lymphoma presentation and treatment were not analyzed. We are implementing a centralized abstraction to collect these data. Finally, cause of death was unknown, and analyses focused on overall survival.
Despite limitations, our study has several strengths. To our knowledge, this is the first detailed description of HIV-associated lymphoma IRIS using a uniformly applied case definition. Although we identified only 56 cases of unmasking lymphoma IRIS, results are drawn from one of the largest multicenter HIV-associated lymphoma cohorts to date, providing a dataset from which characterizing a rare clinical entity like lymphoma IRIS is even possible. Patients studied represent a large and diverse HIV-infected population in routine care across the United States, undergoing regular assessment, in whom lymphoma diagnoses were extensively verified. Additionally, mortality assessment used active and passive surveillance.
In conclusion, 12% of HIV-associated lymphoma patients from a large multicenter cohort met a uniformly applied case definition for unmasking lymphoma IRIS. These patients were similar overall to non-IRIS cases, with similarities also to nonlymphoma IRIS descriptions. Five-year survival was comparable between IRIS and non-IRIS cases, although increased early mortality among IRIS cases was suggested. Detailed studies of lymphoma IRIS immunobiology may have implications for HIV-infected and HIV-uninfected individuals.
Notes
